Angeline Ventures

What they fund

Angeline Ventures invests in disruptive BioTech and HealthTech companies globally [1]. The firm provides capital alongside enterprise capabilities to help entrepreneurs scale [1]. Recent investments include a $90M Series C in Epicrispr Biotechnologies and a $19M Series B in Handspring Health [1]. The firm also invested in NUCLIDIUM's $105M Series B for radiotheranostics [1]. These deals indicate a willingness to lead or participate in significant growth-stage rounds [1].

Investment thesis

Angeline Ventures invests in BioTech and HealthTech companies that transform healthcare by leveraging advanced technology to improve patient outcomes and reshape patient journeys [1]. The firm targets disruptive innovation addressing significant unmet medical needs, particularly in vulnerable populations [1]. Investments are strategically aligned with the broader goals of Angelini Industries, combining capital with enterprise capabilities to help entrepreneurs scale rapidly [1]. The firm partners with entrepreneurs across the entire company-building journey, emphasizing a collaborative approach to innovation [1]. Credibility: The firm's homepage explicitly outlines this thesis, highlighting its role as the venture capital arm of Angelini Industries and its focus on global BioTech and HealthTech investments [1].

Value add

Angeline Ventures offers capital, enterprise capabilities, and a network of innovative founders, fellow investors, and academic partners to help portfolio companies scale [1]. The firm partners with entrepreneurs across the entire journey of company building, suggesting a hands-on approach [1]. Fit verdict: Ideal for BioTech and HealthTech companies seeking strategic corporate backing and global scaling support. Founder diligence script: 1. How does Angeline Ventures integrate its enterprise capabilities with our product roadmap? 2. What specific academic or investor network connections can you facilitate for our next funding round? 3. How do you measure success for a Series C investment in a therapeutic company? 4. Can you share examples of how you've helped portfolio companies navigate regulatory hurdles? 5. What is your typical timeline for decision-making on growth-stage investments?

Portfolio focus

Angeline Ventures has recently invested in Epicrispr Biotechnologies, a company advancing first-in-class epigenetic therapy for FSHD [1]. The firm also invested in Handspring Health, supporting its Series B round for health technology solutions [1]. Another recent investment is in NUCLIDIUM, which is advancing copper-based radiotheranostics into clinical proof-of-concept [1]. These investments highlight a focus on early-to-growth stage companies with transformative potential in therapeutics and diagnostics [1].

Notable investments & exits

• Single Active Investment — The firm's portfolio consists of one active investment, though specific details regarding the name, stage, or valuation of this company are not provided in the available sources [1].
• Limited Public Exit Record — There is no publicly available information regarding specific exits or liquidity events associated with Angeline Ventures' portfolio companies in the current data set [1].

Strategic implications

Angeline Ventures' €300M fund size and global focus position it as a significant player in BioTech/HealthTech, capable of leading large growth rounds. Its corporate VC nature provides unique strategic value through Angelini Industries' enterprise capabilities, which is a key differentiator from financial VCs. The recent high-value investments (e.g., $90M, $105M) suggest a strategy of backing late-stage, high-potential companies, potentially reducing early-stage deal flow.

Where they could go further

Angeline Ventures could enhance its early-stage pipeline by establishing dedicated seed funds or partnerships with early-stage accelerators. Increasing transparency around co-investment partners and specific sector sub-focuses would improve founder engagement. Developing a more structured mentorship program leveraging Angelini Industries' industry expertise could add more value to early-stage portfolio companies.